| Code | 8440C | ||||||||||
| MA number | 44/0226/18-S | ||||||||||
| Product Form: | tbl flm 30x150 mg (blis. Al/PVC) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | Mutual recognition procedure | ||||||||||
| MAH, country: | Teva B.V., Netherland | ||||||||||
| Therapeutic Class: | 44 - CYTOSTATICA | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 60 | ||||||||||
| Container: | blister Al/PVC | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to restricted medical prescription. |
| Legal basis: | Article 10(1) generic application |
| MA issued: | 17.07.2018 |
| SPC: |
SPC_Erlotinib Teva B.V. 150 mg_02.2024.pdf
|
| PIL: |
PIL_Erlotinib Teva B.V. 150 mg_02.2024.pdf
|
| Safety feature | Yes |
| Data update: | 16.11.2022 |
